Edison Investment Research - Bioasis Technologies Inc (BTI.) Bioasis Technologies - New developments in xB3-targeted nucleotides

Report

Edison Investment Research

Sean Conroy

Bioasis Technologies - New developments in xB3-targeted nucleotides

On 31 March 2021 Bioasis announced it has entered a development collaboration with Aposense to develop novel short interfering RNA (siRNA) therapies using Bioasis’s xB3 technology to deliver these therapeutics to the brain. This comes shortly after Bioasis published a paper demonstrating the successful delivery of new genetic material in the brain via this technology. We expect xB3-siRNA drugs to be an important part of the company’s platform.

09/04/2021 5 EN

Underlying

Bioasis Technologies Inc

biOasis Technologies is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for the treatment of central nervous system diseases and diseases of the brain. Co. is engaged in the development of proprietary vectors “Transcend” and “Transcend pep” for the transport of therapeutic agents across the blood brain barrier

See profile

CA09064N1033 TSX Venture Exchange Canada

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Bioasis Provides Corporate Update and Announces Suspension of Operations

Bioasis Provides Corporate Update and Announces Suspension of Operations NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today provided an update on its financial condition and operations...

June 20, 2023 June 20, 2023 1 EN

GlobeNewsWire

Bioasis Provides Update on Business Operations

Bioasis Provides Update on Business Operations NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update on its business operations. On February 28, 2023, Lind Global Macro Fun...

March 23, 2023 March 23, 2023 1 EN

GlobeNewsWire

Bioasis Announces AGM Results and Provides Update on Financial Position

Bioasis Announces AGM Results and Provides Update on Financial Position NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, is pleased to announce that all resolutions were passed by the requ...

February 3, 2023 February 3, 2023 1 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Bioasis Technologies - New developments in xB3-targeted nucleotides

Bioasis Provides Corporate Update and Announces Suspension of Operations

Bioasis Provides Update on Business Operations

Bioasis Announces AGM Results and Provides Update on Financial Position

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe